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Abstract
Background: There is considerable controversy regarding the effectiveness of extracorporeal
shock wave therapy in the management of plantar heel pain. Our aim was to conduct a systematic
review of randomised controlled trials to investigate the effectiveness of extracorporeal shock
wave therapy and to produce a precise estimate of the likely benefits of this therapy.
Methods: We conducted a systematic review of all randomised controlled trials (RCTs) identified
from the Cochrane Controlled trials register, MEDLINE, EMBASE and CINAHL from 1966 until
September 2004. We included randomised trials which evaluated extracorporeal shock wave
therapy used to treat plantar heel pain. Trials comparing extra corporeal shock wave therapy with
placebo or different doses of extra corporeal shock wave therapy were considered for inclusion in
the review. We independently applied the inclusion and exclusion criteria to each identified
randomised controlled trial, extracted data and assessed the methodological quality of each trial.
Results: Six RCTs (n = 897) permitted a pooled estimate of effectiveness based on pain scores
collected using 10 cm visual analogue scales for morning pain. The estimated weighted mean
difference was 0.42 (95% confidence interval 0.02 to 0.83) representing less than 0.5 cm on a visual
analogue scale. There was no evidence of heterogeneity and a fixed effects model was used.
Conclusion: A meta-analysis of data from six randomised-controlled trials that included a total of
897 patients was statistically significant in favour of extracorporeal shock wave therapy for the
treatment of plantar heel pain but the effect size was very small. A sensitivity analysis including only
high quality trials did not detect a statistically significant effect.
Background
Plantar heel pain (plantar fasciitis) can be debilitating,
often with severe limitations on activity. Typically,
patients present with pain in the plantar aspect of the heel
whilst walking, particularly after rest. Pain on first weight-
bearing in the morning is a prominent diagnostic feature.
The precise nature of the condition is poorly understood
but literature suggests it is an enthesitis at the attachment
of the plantar fascia to the plantar medial tubercle of the
calcaneum.
A systematic review of the management of heel pain has
highlighted the paucity of evidence for managing the con-
dition. The review concluded that treatments used to
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night splints, orthoses and stretching regimes, seem to
bring only marginal gains [1]. Extracorporeal shock wave
therapy (ESWT) was originally used for lithotripsy, but
within the last 10 years has become increasingly used to
treat musculoskeletal injuries including calcific tendinitis
of the shoulder [2], lateral epicondylitis (tennis elbow) [3-
5], non-union or delayed osseous union [6] and plantar
heel pain [1,7].
Non-systematic review articles, specific to the effective-
ness of ESWT in the treatment of plantar heel pain, pro-
duce conflicting conclusions. One 'biometric' review [7]
suggested that there is insufficient evidence on which to
draw conclusions on the effectiveness of EWST and that
more trials are required to detect any benefits from the
intervention. Bodekker et al [7] incorporated all levels of
evidence, including 4 randomised trials, that did not per-
mit pooling of data or statistical synthesis. Study charac-
teristics and quality assessments were provided in the
form of lists. Ogden et al's review of ESWT [8] used a "vote
counting" method to conclude that ESWT was a useful
treatment for plantar heel pain. No quality assessment of
the included trials was presented, but a quantitative data
synthesis claims success rates ranging from 34% to 88%.
Unfortunately, these estimates are not clearly attributed to
any specific outcome. Heller and Niethard [9] identified
poor trial methodological quality as a barrier to an assess-
ment of the effectiveness of ESWT and were unable to
demonstrate any benefit from the treatment in this narra-
tive review article.
There is considerable controversy emerging regarding the
use of ESWT for plantar heel pain. Three recent ran-
domised controlled trials have failed to demonstrate a
beneficial effect from the use of ESWT [10-12] and it has
been suggested that no more clinical trials should be con-
ducted to evaluate this therapy as a treatment for the pain-
ful heel [11]. A narrative review article [13] concluded that
the available data do not provide substantive support for
its use but this prompted correspondence which illus-
trates the defense for this electrophysical modality in the
management of heel pain [14,15]
The purpose of this systematic review was to conduct a rig-
orous evaluation using a quantitative synthesis of evi-
dence from randomised controlled trials to make a precise
estimate of the effectiveness of ESWT. Our aim was to
determine if ESWT is effective in the treatment of patients
with plantar heel pain when compared with a control
group.
Methods
Search strategy
Randomised controlled trials were identified by searching
the following data sources: The Cochrane Musculoskeletal
Injuries Group specialized register of trials (August 2003),
the Cochrane Central Register of Controlled Trials (The
Cochrane Library issue 3, 2003), MEDLINE (from 1966 to
September 2004), EMBASE (from 1982 to September
2004), CINAHL (from 1982 to September 2004) and ref-
erence lists of articles and dissertations. In Medline (Sil-
verPlatter), the first two levels of the optimum search
strategy [16] were combined with the following subject-
specific search terms:
1. HEEL* and SYNDROME*
2. (JOG* or TENNIS* or POLICE* or GONORREAL) near
HEEL*
3. PLANTAR near FASCI*
4. explode "FASCIITIS"/ all subheadings
5. (PLANTAR or HEEL* or CALCAN* or FOOT*) near
PAIN*
6. HEEL near SPUR
7. "CALCANEUS"/ all subheadings
8. #1 or #2 or #3 or#4 or #5 or #6 or #7
Further details of the search strategy and details of the
hand search have been previously published [1], [see
Additional file 1].
Study selection
We considered all randomised controlled trials of plantar
heel pain treatments for inclusion in the review. Trials
comparing ESWT with placebo or different doses of ESWT
were considered. Participants with a clinically confirmed
diagnosis of plantar heel pain were included. Adult partic-
ipants in any trial whether they were part of the general
population, athletes, or individuals with seronegative
arthropathies and enthesopathies were also considered
for inclusion. Any age group was admissible. It was our
intention that trials involving children alone, or dealing
specifically with young athletes, would be analysed sepa-
rately. We excluded trials evaluating treatments for plantar
heel pain arising from calcaneal fractures, calcaneal
tumours, previous surgery for plantar heel pain, or poste-
rior heel pain.
Outcome measures
We chose morning pain as our a priori primary outcome
measure for this systematic review. We consider it to be
the most important outcome as it is the single mostPage 2 of 11
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(pain on first rising, first step pain or start up pain) is uni-
versally reported by patients complaining of plantar heel
pain and it is also strongly diagnostic for the condi-
tion[17]. The secondary outcome measures were walking
pain, pressure pain, any measure of disability, quality of
life measures and adverse events.
Data abstraction
Two of the authors (CT,FC) independently applied the
inclusion and exclusion criteria to each trial and then
extracted data regarding details of the patients (number,
mean age and age range, inclusion and exclusion criteria),
details of the interventions, nature and timing of outcome
measures. Disagreements were resolved by discussion of
the articles by the reviewers. We wrote to trialists for addi-
tional information on trial methodology (method of ran-
domization) and results (usually requests for data not
presented in the original reports such as standard devia-
tions or some other measure of variance).
Validity assessment
A quality assessment tool[18] adapted for use in a related
systematic review of interventions for the treatment of
plantar heel pain for the Cochrane Library [1] was applied
to each of the included trials. This addressed the following
questions:
1. Was the generation of randomization sequence
described?
2. Was the method of allocation concealment described?
3. Was an intention to treat analysis used?
We assessed intention to treat on the basis of whether
patients were analyzed according to the allocated treat-
ment irrespective of whether this treatment was delivered
or not.
4. What number of patients were lost to follow-up?
In assessing loss to follow-up we considered whether
authors had presented numbers lost and timing, and the
reasons for the loss. We presented the numbers lost to fol-
low up as percentages.
5. Was the outcome assessment blind?
6. Was the patient blind to treatment allocation?
This led to each trial being attributed a quality score out of
a maximum of 6 points (Table 1.).
Quantitative data synthesis
When measures of variance were not available from the
original report, it was our intention to derive these from
p-values. When data were available for a pooled estimate
of the impact of intervention it was intended that meta-
analyses would be conducted for direct comparisons. We
intended to present weighted mean differences and 95%
confidence intervals for outcomes for each randomised
controlled trial and group them in relevant sub-groups
according to the specific question they addressed. We
intended to use a fixed effects model to estimate the
pooled effect as our primary analysis where no evidence of
heterogeneity was detected [19]. However, if evidence of
heterogeneity was found to be present we intended to use
a random effects model [20]. Meta-analyses were gener-
ated using RevMan software. We planned to perform sub-
group analyses and sensitivity analyses, regarding any
anomalies with the included trials, methodological scores
and industry sponsorship. We proposed to perform a fun-
nel plot to detect publication bias.
Table 1: Quality assessment of included trials
Author randomisation 
sequence
allocation 
concealment
Assessor 
blind
Patient 
blind
Loss to follow 
up at trial end
Intention 
to treat
Quality 
score
Abt et al [21] No No Yes Yes 11% No 3
Buch et al [27] Yes Yes Yes Yes 4% No 5
Buchbinder et al [10] Yes No Yes Yes 6% Yes 5
Cosentino et al [33] No No Yes Not stated Not stated No 1
Haake et al [11] Yes Yes Yes Yes 16% Yes 6
Krischek et al [22] No No No Not stated 6% No 1
Ogden et al [28] No No Yes Yes 1.5% No 3
Rompe et al [32] No No Yes Yes 16% No 3
Rompe et al [30] No No No Yes Not stated No 1
Rompe et al [31] No No Yes Yes 20% No 3
Speed et al [12] No No Yes Yes 14% Yes 4Page 3 of 11
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Selection of trials
The search strategy identified a total of 205 studies, of
which 15 were identified as RCTs that evaluated ESWT for
plantar heel pain. Two of these were translated from Ger-
man into English [21,22]. Four trials [23-26] were
excluded from the review: in one, the intervention and
control groups were treated at different time points mak-
ing valid comparisons of patient outcomes in both groups
impossible [24]. The second trial contained five year fol-
low-up data from an RCT published in 1996 [23]. These
trial data were confounded by placebo patients receiving
additional therapies after 12 weeks. The third [25] and
fourth [26]excluded trials were duplicated data previously
reported by Buch [27] and by Ogden [28]respectively. The
flow diagram in Figure 1 provides details of the included
and excluded trials and those included in the final meta-
analysis[29].
Description of included studies
Eleven RCTs were included in this review and they
reported data published between 1996–2003 from trials
involving 1290 patients [10-12,21,22,27,28,30-33]. Table
1 shows the quality assessment scores and Table 2 and
Table 3 the baseline data. The trials evaluated different
doses of ESWT against either a placebo dose or a control
dose so low as to be considered therapeutically ineffective
[10] (Table 4). Only five of the trial reports contained
summary statistics to permit pooling of data collected at
12 weeks in a forest plot [10-12,27,28]. Standard devia-
tions were derived from the p value reported in one man-
uscript in order to incorporate a sixth trial in the meta-
analysis, the timing of the outcomes varied between 17
and 20 weeks for this trial [21].
Table 2 and table 3 present details of the baseline pain
scores, and demographic variables for participants from
all eleven included trials. All included adult patients only.
The duration of pain was greater than 6 months in ten tri-
als [11,12,21,22,27,28,30-33]. In one trial [10] the dura-
tion of pain was shorter than six months for some patients
but no patient had a duration of pain less than 8 weeks.
The duration of pain ranged from 8–600 weeks and 8–
980 weeks for the ESWT and placebo groups respectively.
The median values for duration of pain were 36 weeks and
43 weeks. The demography of the patients in this system-
atic review of ESWT for plantar heel pain was similar to
those patients who have participated in evaluations of
other interventions for heel pain [1]. The effects of ESWT
in people who had a calcaneal spur on x-ray [4,32], were
running athletes [31], were being considered for surgical
intervention [30,32,32], had failed to respond to conserv-
ative treatments [27,28,30,32], or were defined as recalci-
trant cases [22], were all included in this systematic
review.
There was diversity in the types of primary and secondary
outcomes collected from patients in the 11 RCTs. Table 5.
summarizes the most commonly reported outcomes
measures indicating, where available, the outcomes pro-
vided. With the exception of three trials [22,30,32] all pre-
sented data for visual analogue scale scores of morning
pain. Walking pain is a relevant outcome measure and
was reported by eight trials [10,11,21,22,30,32,33]. Only
two of these trials contained compatible data [30,32] and
insufficient data are provided to permit pooling. The
remaining trials described a wide variety of walking ability
using incongruous scoring systems. Six of the trials
[11,21,22,30,32,33], show a favourable outcome for
walking pain after ESWT. Resting and night pain are not
common symptoms of heel pain, in our experience, but
data for these outcomes were collected in four trials
[12,21,30,32]. Five trials reported the collection of pres-
sure pain outcomes from the application of pressure from
either a manual application or an electronic device
[21,27,28,30,32]. Other outcomes reported were Roles
and Maudsley scores [11,21,27], Maryland Foot
score[10], SF12 [27], SF36 [10], problem elicitation tech-
nique [10] and The Ankle Hindfoot Scale [31].
Of the 11 RCTs that met our inclusion criteria, eight were
placebo controlled trials [11,12,21,27,28,31-33]. Three
trials used a low, sub-therapeutic dose as control
[10,22,30]. The doses for the intervention groups and
methods used to disable the equipment for the placebo
group and the sub-therapeutic groups are provided in
Table 2 and Table 3. The dose of ESWT varied between tri-
als in both energy levels and the number of impulses
administered. With the exception of two trials, [10,12], all
excluded patients had the condition for less than six
months. Only one trial [10] did not require patients to
have exhausted conservative therapies for recalcitrant
plantar heel pain before embarking on treatment with
ESWT but information presented reveals that the majority
of patients did receive a number of conservative therapies.
Krischek et al [22] and Rompe et al [31] included only
patients whose next management option was surgery.
Quantitative data synthesis
Figure 2. shows the pooled analysis of data from 6 trials
which produce a weighted mean difference of 0.42 in
favour of ESWT. This treatment effect is statistically signif-
icant (p = 0.04), but the effect is small (95% confidence
interval of 0.02 to 0.83) with respect to morning pain
(first step pain). All outcomes were taken at 12 weeks,
except for one trial [21] which reported the first outcome
measured at (on average) 19 weeks. There was no evi-
dence of heterogeneity (p = 0.11) and a fixed effects
model was used.Page 4 of 11
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Progress through the stages of the meta-analysis [29].
Potentially relevant RCTs identified and screened for retrieval
(n= 15)
RCTs retrieved for more detailed evaluation (n= 15)
RCTs excluded with reasons (n = 0)
RCTs excluded with reasons (n= 4)
Hammer 2002.Confounded. Differences in timing of outcomes
Rompe 2002. Follow-up of previously confounded sample
Theodore 2004,Ogden 2004. Duplication of previously
reported trial.
Relevant RCTs to be included in the meta-analysis (n= 11)
RCTs excluded from meta-analysis, with reasons (n= 5)
Rompe 1996a did not collect morning pain outcomes or
present means with variance. Rompe 1996b did not collect
morning pain outcomes. Krischek 1998 did not collect morning
pain outcomes. Consentino 2001 did not present data as
means and variance. Rompe 2003, no outcomes at 12 weeks
RCTs included in meta-analysis (n=6)Page 5 of 11
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the trial by Abt et al [21], the only trial for which we had
to impute measures of variance. The resultant weighted
mean difference was 0.30 in favour of ESWT, with a 95%
confidence interval of -0.12 to 0.72. This effect is no
longer statistically significant.
We performed a sensitivity analysis for the quality of trial
reports by dividing the six trials into two groups; those
that received a quality assessment score of four or more
[10-12,27] and those receiving a score of less than four
[21,28] to perform meta-analyses using fixed effects mod-
els. The four better quality trials produced a non signifi-
cant result (weighted mean difference 0.21, 95%
confidence interval -0.29 to 0.70 cm, p = 0.41) whereas
the two trials scoring less than three produced a signifi-
cant result in favour of active treatment (weighted mean
difference -0.90, 95% confidence interval -1.62 to -0.19, p
= 0.01).
Adverse events
Two trials did not report adverse events [12,30]. Buch-
binder et al [10] reported pain for one week by one patient
in each arm of the trial; one patient in the active arm of the
trial reported a sensation of heat and numbness, whilst
another complained of bruising. One patient in the pla-
cebo arm complained of a burning sensation in the heel
and ankle. Ogden et al [28] reported 38 procedure related
complications, 18 of which occurred in the active treat-
ment arm. The most common procedure related compli-
cations were mild neurological symptoms (numbness,
tingling). One patient who suffered a plantar fascial rup-
Table 2: Baseline characteristics of participants in respective trials. (N/a- data not available).
Author Age mean (SD and/or range) years Female:male (% female) Mean BMI (SD)
Treatment group Control group Treatment group Control group Treatment group Control group
Abt et al [21] 56.5 57.4 11:6 (64.7) 9:6 (60) 30.1 28.5
Buch et al [27] 50.4 (10.3, 26–69) 53.0 (9.7, 31–72) 61:14 (81.3) 46:26 (63.9) 28.9 28.5
Buchbinder et al [10] 52.2 (12.8) 54.2 (12.0) 46:3 (57.5) 47:3 (58.0) 29.5 28.9
Cosentino et al [33] 55.6 (45–68) 18:12 (60.0) 25:5 (83.3) N/a N/a
Haake et al [11] 53.1 (10.8) 52.9 (10.8) 98:37 (72.6) 106:30 (77.9) 29.4 (4.9) 29.7 (4.8)
Krischek et al [22] 54.0 55.0 (56.0) (72.0) N/a N/a
Ogden et al [28] 49.6 (20–79) 171 (65.9) N/a N/a
Rompe et al [32] 44.0 (26–61) 49.0 (31–63) 21:29 (42.0) 20:30 (40.) N/a N/a
Rompe et al [30] 47.0 (26–61) 51.0 (31–58) 5:10 (33.3) 6:9 (40) N/a N/a
Rompe et al [31] 43.0 (32–59) 40.0 (30–61) 10:12 (45.5) 13:10 (56.5) N/a N/a
Speed et al [12] 51.7 (25–76) 52.5 (30–73) 26:20 (56.5) 25:17 (59.5) N/a N/a
Table 3: Baseline characteristics of participants in respective trials continued (N/a- data not available).
Author Duration of heel pain Median (SD and/or range) months Base line morning pain VAS score (SD)
Treatment group Control group Treatment Group Control group
Abt et al [21] 19.0 19.0 5.7 5.3
Buch et al [27] 20.7 (21.1, 6–120) 24.0 (21.1,6–99) 7.7 (1.4) 7.7 (1.5)
Buchbinder et al [10] 9.0 (2–150) 10.8 (2–222.5) 7.3 (2.5) 6.8 (3.2)
Cosentino et al [33] 8.2(6–12) 8.2(1.2) N/a N/a
Haake et al [11] 13.0 (10–24) 13.0 (9–24) 7.8 (2.4) 7.7 (2.3)
Krischek et al [22] 22.0 23.0 N/a N/a
Ogden et al [28] 32.2 35.9 8.1 8.2
Rompe et al [32] 8.0 (6–19) 10.0 (6–20) N/a N/a
Rompe et al [30] 16.0 (12–36) 22.0 (12–38) N/a N/a
Rompe et al [31] 20.0 (12–60) 18.0 (12–72) 6.9 (1.3) 7.0 (1.3)
Speed et al [12] 16.7 (12–312) 13.5 (12–312) 7.4(2.0) 7.0(2.0)Page 6 of 11
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Author Included in 
meta-analysis
Local anesthetic 
to both groups
Details of placebo/sub 
therapeutic dose
Ultrasound 
guidance
N Weighted mean 
difference – morning 
pain (95%CI)
Timing of 
outcomes 
(weeks)
Abt et al [21] yes yes Absorbent block Not stated 32 2.00 (0.47 to 3.53) 19,32
Buch et al [27] yes yes Absorbent foil yes 150 0.70 (-0.26 to 1.66) 12
Buchbinder et al [10] yes no 6000 to 7500 vs 300 impulses yes 178 -0.50 (-1.55 to 0.55) 6,12
Cosentino et al [33] no no Not stated yes 60 Not available 4,12
Haake et al [11] yes yes Polythene foil barrier Not stated 272 0.50 (-0.31 to 1.31) 6,12, 52
Krischek et al [22] no no 1500 vs 300 impulses Not stated 50 Not available 6,12
Ogden et al [28] yes yes* Styrofoam block no 260 0.56 (-0.26 to 1.38) 4,8,12
Rompe et al [32] no no 3000 vs 30 impulses Not stated 119 Not available 12, 52
Rompe et al [30] no no 1 cm gap no 36 Not available 3,6,12,24
Rompe et al [31] no no Reflecting pad yes 45 2.60 (1.37 to 3.83) 26,52
Speed et al [12] yes no Focus outside patient yes 88 -0.36 (-1.66 to 0.94) 4,8,12,24
* Local anaesthetic was used for both groups but was different for the placebo group and the treatment group.
Table 5: Summary of most commonly reported outcomes measures at 12 weeks (or nearest point to). P values relate to active 
treatment versus placebo or reduced dose. * Indicates a statistical significant difference in favour of EWST treatment. Figures in 
parentheses are 95% confidence intervals. Where p-values were not provided, the values for mean and standard deviations [SD] are 
given, I indicates EWST group, II indicates placebo group. "Favours ESWT" indicates a better outcome for ESWT where neither of 
the previous details are provided.
Author Morning/
start up 
pain
Overall pain Walking 
ability /
activity 
related
Foot 
specific 
score
Pain at rest 
(100 mm 
VAS)
Pain on 
pressure
Night pain/
evening pain
End point
Abt et al [21] P = 0.016* - Favours 
ESWT
- P = 0.01* P = 0.26 P = 0.01* 19 weeks
Buch et al [27] P = 0.0309 - P = 0.7377 I. (49.1–71.5)
II.(32.9–55.9) 
AOFAS
- Not 
significant
P < 0.4338 12 weeks
Buchbinder et al [10] P = 0.92 
(-12.7 – 13.1)
P = 0.99 
(-10.3–11.5)
P = 0.0.72 
(0.6–1.9)
P = 0.85 
(-7.6–5.3) 
Maryland FS
- - - 12 weeks
Cosentino et al [33] P < 0.0001* - P < 0.0001* - P < 0.0001* - - 12 weeks
Haake et al [11] I mean = 4.0, 
SD = 3.2
II mean = 4.5, 
SD = 3.0
- Favours 
ESWT
- I mean = 2.4, 
SD = 2.6
II mean = 
2.4, SD = 2.5
I mean = 4.0, 
SD = 3.2
II mean = 4.3, 
SD = 3.2
I mean = 1.5, 
SD = 2.4
II mean = 1.8, 
SD = 2.5
12 weeks
Krischek et al [22] - Favours 
ESWT
Favours 
ESWT
- - Favours 
ESWT
- 12 weeks
Ogden et al [28] Favours 
ESWT
- - - - Favours 
ESWT
- 12 weeks
Rompe et al [32] - - Favours 
ESWT
- P < 0.0001* P < 0.0001* P < 0.0001* 12 weeks
Rompe et al [30] Favours 
ESWT
Favours 
ESWT
P < 0.0001* - P < 0.05* P < 0.0001* P < 0.05* 12 weeks
Rompe et al [31] P = 0.0004* - - P = 0.0025* 
AOFAS
- - - 26 weeks
Speed et al P = 0.664 
(0.656–1.271)
P = 0.246 
(0.626–1.093)
- - - - P = 0.378 
(0.620–1.166)
12 weeksPage 7 of 11
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ple cortisone injections prior to embarking upon
treatment with ESWT.
Haake et al [11] reported a statistically significant differ-
ence in the number of side effects in the active and pla-
cebo groups; OR 2.26 (95% confidence interval 1.02 to
5.18) [11]. These were; skin reddening, pain and local
swelling. The same authors [11] also describe less frequent
complaints of dizziness, sleep disturbance haematoma,
nausea and hair loss as non-serious effects and discounted
one report of a deep vein thrombosis in a placebo partici-
pant as a co-incidental event. In two trials, [31,32] the
unpleasant nature of ESWT experienced by patients dur-
ing treatment was reported. These sensations were
regarded as less unpleasant than local cortisone infiltra-
tion. Krischek et al [22] reported that there were no
adverse events noted in trial participants.
Industry sponsorship
Companies who produce ESWT equipment provided
some sponsorship in three trials [11,27,28] (Table 6).
One trial [28] was the basis for the first Food and Drug
Administration (FDA) approval for ESWT. A financial
interest with HealthTronics was declared in correspond-
ence following the publication of the trial [34,35]. The
trial by Buch et al [27] was sponsored by Dornier Med
tech Inc and the data were also used to gain approval for
Pooled estimates of 10 cm VAS scores for morning pain at 12 weeksFigure 2
Pooled estimates of 10 cm VAS scores for morning pain at 12 weeks
Table 6: Details of ESWT devices, dose of impulses administered.
Author Device ESWT impulse dose × 
number of treatments
Low energy/ high energy 
(energy level)
Details of sponsorship
Abt et al [21] Ossatron High Medical 
Technology
1000 × 2 Low Energy (0.08 mJ/mm2 No declaration
Buch et al [27] Epos Ultra Dornier Medical 
Systems
3800 total High energy (0.03–0.36 mJ/
mm2 -total 1300 mJ/mm2)
Industry sponsored trial but this was 
not declared
Buchbinder et al [10] Epos Ultra Dornier Medical 
Systems
2000–2500 × 3 Low energy (0.02–0.33 mJ/
mm2-total 1000 mJ/mm2)
Declared funding – not from 
industry
Cosentino et al [33] Orthima Direx Med Sys Ltd 1200 × 6 Not stated (0.03–0.4 mJ/
mm2)
No declaration
Haake et al [11] Epos Ultra Dornier Medical 
Systems
4000 × 3 Low energy (0.08 mJ/mm2-
total 0.96 J/mm2)
Declared: industry provided 
machine
Krischek et al [22] Osteostar Siemans 500 × 3 Low energy (0.08 mJ/mm2) No declaration
Ogden et al [28] Ossatron High Medical 
Technology
1500 total High energy (0.22 mJ/mm2-
total 324.25 J)
Industry sponsored trial but this was 
not declared
Rompe et al [32] Osteostar Siemans 1000 × 3 Low energy (0.06 mJ/mm2) No declaration
Rompe et al [30] Osteostar Siemans 1000 × 3 Low energy (0.06 mJ/mm2) No declaration
Rompe et al [31] Sonocur Plus Siemens 2100 × 3 Low energy (0.16 mJ/mm2) No declaration
Speed et al [12] Sonocur Plus Siemens 1500 × 3 Low energy (0.06 mJ/mm2) Declared funding – not from 
industry
Review: Interventions for treating plantar heel pain
Comparison: 22 morning pain - eswt
Outcome: 01 VAS 10cm
Study ESWT Placebo/low dose WMD (fixed) Weight WMD (fixed)
or sub-category N Mean (SD) N Mean (SD) 95% CI % 95% CI
Speed 2003 42 4.80(3.20) 46 5.16(3.00) 9.83 -0.36 [-1.66, 0.94]
Ogden 2001 91 4.61(2.86) 98 4.05(2.89) 24.67 0.56 [-0.26, 1.38]
Abt 2002 15 3.40(2.20) 17 1.40(2.20) 7.11 2.00 [0.47, 3.53]
Buch 2002 74 4.10(3.10) 76 3.40(2.90) 17.96 0.70 [-0.26, 1.66]
Buchbinder 2002 85 4.40(3.40) 81 4.90(3.50) 15.04 -0.50 [-1.55, 0.55]
Haake 2003 129 4.50(3.40) 127 4.00(3.20) 25.38 0.50 [-0.31, 1.31]
Total (95% CI) 436 445 100.00 0.42 [0.02, 0.83]
Test for heterogeneity: Chi² = 8.92, df = 5 (P = 0.11), I² = 43.9%
Test for overall effect: Z = 2.03 (P = 0.04)
-10 -5 0 5 10
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from the FDA. Haake et al [11] stated no competing inter-
ests but did declare that a manufacturer of ESWT equip-
ment had provided the machine used in the trial. Two
trials [10,12] declared funding from sources other than
industry. In the remaining trials there was no explicit dec-
laration of competing interests [21,22,30-33] (Table 6).
Discussion
The lack of convergence of findings from randomised
evaluations of EWST for plantar heel pain has resulted in
clinical uncertainty about its effectiveness. Within this
systematic review, we have been able to evaluate the effec-
tiveness of ESWT in a meta-analysis and used the pooled
data to arrive at more precise conclusions about its useful-
ness in clinical practice.
The meta-analysis shows a statistically significant benefit
with ESWT on plantar heel pain from outcomes of 897
patients' VAS scores of morning (first-step) pain assessed
at or around 12 weeks but we do not consider this clini-
cally significant since the observed benefit equates to less
than one half centimeter on a 10 cm VAS. The 95% confi-
dence interval is compatible with a mean treatment bene-
fit of at most 0.83 cm. A sensitivity analysis including only
those higher quality trials did not produce evidence of a
statistically significant benefit. Only one trial included in
the review discussed what might constitute a clinically
meaningful reduction in plantar heel pain: Buchbinder et
al [10], suggest that 0.7 cm reduction of heel pain may not
be clinically relevant.
We included one trial in the meta-analysis which used
sub-clinical doses as controls [10] and combined these
patient outcomes with those from trials which used sham
treatments as controls [11,12,21,27,28]. All six trials [10-
12,21,27,28] also used different doses of ESWT but,
despite the differences in the use of control interventions
and doses, no evidence of heterogeneity in the patient
outcomes was detected in the pooled estimate (figure 2).
Nor does there appear to be a dose-response relationship
for ESWT; trials using both high and low doses have
reported similar effects as is evident from the estimates
from the trials by Haake et al [11] and Abt et al [21] (Table
6, figure 2).
We were grateful to the authors of trials included in this
review who provided supplementary data in response to
our correspondence [10,11] but disappointed that data
from all 11 trials were not available to us. Five trials were
not included in the meta-analysis either because adequate
data were not provided [22,33] the timing of the out-
comes differed greatly from the other trials [31] or the out-
comes were clinically irrelevant [30,32]. Consequently,
information about the effects of ESWT in 310 patients
with heel pain was effectively lost to re-analysis. Any
future reporting of patient outcomes should include
means of pain scores with measures of variance in order
that new trials can be included in meta-analyses and
weighted mean differences and confidence intervals calcu-
lated [36].
Rompe et al conducted a small trial (n = 40) which evalu-
ated the benefits of ESWT in running athletes [31] and
reported a mean difference of 2.60 (95% confidence inter-
val 1.37 to 3.83) for morning pain at 6 months. This effect
size is statistically significantly different from the com-
bined outcomes presented in Figure 2 but not statistically
different from the mean difference in outcomes reported
in the small trial by Abt et al [21] 2.00 (95%confidence
interval 0.47 to 3.53) at 19 weeks (n = 37). That the two
smallest trials included in the review should produce
between-group comparisons of pain in the morning that
reach statistical significance when estimates from larger
studies do not is surprising. Sample size is an important
factor in experimental bias in clinical trials as effect size
estimates from small studies can be highly variable [37].
The effect sizes from these small studies may be due to
ESWT being beneficial in certain sub groups within the
population (e.g. runners), or may be as a result of a failure
to blind the participants successfully to their treatment
allocation, as previously reported by one of the authors
[30]. Alternatively, these data may be aberrant values that
are more likely to occur by chance in small studies than
larger ones [38].
ESWT was not considered a suitable therapy for the first-
line management of heel pain by the majority of the
investigators. This may be because of limited access to this
relatively new and expensive equipment or, more likely,
because of the favourable natural history of this
condition.
In the absence of a validated heel pain specific outcome
measure, our a priori choice of morning pain as the pri-
mary outcome measure was vindicated by eight of the of
the eleven included trials collecting morning pain or first
step/start up pain outcomes. One trialist [10] used a prob-
lem elicitation technique which confirmed "walking after
getting out of bed in the morning" as the most frequently
reported problem by patients with heel pain. We had
planned to pool additional secondary outcome measures,
such as walking pain, but this was not possible because of
the diversity of the outcome measures used and differ-
ences in the data collected. Some of the outcomes that
have been used to assess the effects of treatments were
clinically irrelevant in our opinion [30-33]. Night pain
and resting pain are not symptoms that we commonly
encounter in patients seeking treatment for plantar heel
pain. Three trials [11,21,27] incorporated the RolesPage 9 of 11
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2005, 6:19 http://www.biomedcentral.com/1471-2474/6/19Maudsley scale and one trial [10] used the Maryland Foot
Score as measures of disability. It is commendable that
two of the investigators [10,27] used generic health out-
comes, SF36 and SF 12 respectively. Future trials should
include outcomes of disability as well as the impact on
health related quality of life and not just pain when assess-
ing the effect of interventions for heel pain.
Of the eight outcomes listed in Table 5, only "pain at rest"
is distinct with four of the five trials [11,21,30,32,33]
favouring ESWT compared with placebo or reduced dose.
As previously discussed, this outcome measure is not a key
feature of plantar heel pain. All other outcome measures
are equivocal.
Minimal side effects were reported by Abt et al [21] and
Buchbinder et al [10]. The most frequently reported
adverse event from the use of ESWT is pain [11,27,32,33]
which appeared to affect some patients both during and
after the procedure.
The quality of reporting varied amongst trials. The three
most recent trials [10,11,31] all received above average
quality scores for trial reporting. This is an encouraging
development for those interested in improving the out-
comes for patients who have heel pain and may reflect
both the use of checklists such as the CONSORT state-
ment [36] for trial reports now demanded by many jour-
nal editors as well as a greater awareness of good trial
reporting practice by trialists themselves. There was how-
ever, a contrast in the results obtained from the four better
quality trials, scoring three or above, when meta-analyzed
separately from the two poorer quality trials. Better qual-
ity trials did not favour ESWT whilst the poorer quality
ones did.
Industry sponsorship
At least two of the trials included in our meta-analysis,
received some form of sponsorship from a company man-
ufacturing ESWT [27,28] although this has not been made
explicit within the published papers. Both these trials
reported significant benefit from ESWT. One further trial
Haake et al [11] declared being supplied with the ESWT
equipment and reported no statistically significant effects
between the two groups. Six of the trials [21,22,30-33]
have not made it clear whether there is any conflict of
interest or not. In a systematic review to investigate
whether the funding of drug studies by the pharmaceuti-
cal industry is associated with bias, Lexchin et al [39] con-
cluded that industry sponsorship was more likely to
produce results favouring the sponsors' product than
studies funded from other sources.
Publication bias
In view of concerns about publication bias, it is encourag-
ing that three large, negative trials have been published in
high impact journals. We were unable to recognize the
existence of small, unpublished studies showing no statis-
tically significant benefits. However, the existence of any
such trials would only serve to endorse the findings of the
meta-analysis in this systematic review.
Conclusion
It has been suggested that the poor outcomes reported by
recent randomised controlled trials evaluating ESWT for
plantar heel pain means no further trials should be con-
ducted [11]. A meta-analysis of data from six randomized
controlled trials that included a total of 897 patients was
statistically significant in favour of extracorporeal shock
wave therapy for the treatment of plantar heel pain but the
effect size was very small. When the two poorest quality
trials, and therefore the greatest source of bias, are
removed from the meta-analysis, the result is not
statistically significant. This systematic review does not
support the use of ESWT for plantar heel pain in clinical
practice.
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